Tirzepatide is a once-weekly injectable GIP/GLP-1 dual agonist peptide drug used to treat type 2 diabetes and obesity. It lowers blood sugar, suppresses appetite, and leads to approximately 20% weight loss over 72 weeks with minimal gastrointestinal side effects.
Our products are provided in a freeze-dried, lyophilized powder that is vacuum sealed in a sterile vial format that typically require reconstitution with an applicable solvent or solution and intended for research use only.